PROGRESS IN GYNECOLOGIC CANCER RESEARCH: THE GYNECOLOGIC ONCOLOGY GROUP EXPERIENCE

摘要

Since 1970, the Gynecologic Oncology Group (GOG) has been a leader in clinical research in gynecologic oncology. Currently comprising fifty-nine institutions and their affiliates in the United States, Canada and elsewhere, GOG has defined, principally through phase III randomized clinical trials, the standard of care for several stages and types of female pelvic cancer. This review will briefly summarize, in the context of research done concurrently by other groups and institutions, important GOG trials that have moved the field forward, especially in ovarian, endometrial, and cervical cancer. The role of cisplatin, carboplatin and paclitaxel as well as other drugs and combinations in gynecologic cancer has been extensively studied by GOG, as has chemoradiation in cervical cancer. Surgical staging of cervical and endometrial cancers has provided new insights and guidance for management. The benefits and limitations of radiation therapy in these diseases have been carefully examined. Thus, the stage has been set for further progress in this field.